Research Reports

Key takeaways

Revenue increased to $132.9M from $3.1M year-over-year as YUTREPIA sales post-2025 launch replaced prior service revenue.

Operating income turned $61.5M positive (46.3% margin) from $35.4M loss, reflecting strong product gross margins amid R&D growth.

Net income reached $52.9M versus $38.4M loss, delivering $0.52 diluted EPS due to revenue scale overcoming prior operating deficits.

Operating cash flow provided $53.0M, reversing $30.7M prior use, primarily from higher net income adjusted for non-cash items despite working capital changes.

Free cash flow of $50.2M after $2.8M capex supports self-sufficiency, with liquidity sufficient for operating expenses and capital needs beyond one year per current plans.

Full analysis

Liquidia Corporation reported transformative Q1 2026 results, driven by YUTREPIA's commercial launch in Q2 2025. Revenue jumped to $132.9 million from $3.1 million in the prior year, reflecting the shift from service revenue to product sales following the inhalational therapy's market entry. This scale enabled operating income of $61.5 million at a 46.3% margin, a stark reversal from the $35.4 million loss, as YUTREPIA's gross margins absorbed rising expenses.

Liquidity supports the path ahead. Historically financed via revenues, equity, debt, and notes, current cash funds operating expenses, capital needs, and minimum covenants beyond one year from filing, absent new financing. R&D spending may rise with L606 trials, though levels depend on project progression. These results signal Liquidia's transition to sustainable operations, with YUTREPIA as the cornerstone amid pipeline advancement.

LQDA · Liquidia Corporation

Summary

Key takeaways

Full analysis